New data from the ongoing Phase 3 study further defines the effectiveness of VUMERITY® (Dilosimil fumarate) and improved gastrointestinal tolerance
Compared with Ocrevus® (ocrelizumab), the actual findings evaluated the quality of life benefits associated with TYSABRI® (natalizumab)
Other real-life discoveries report the positive benefits of PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a) in elderly patients with multiple sclerosis
Cambridge, Massachusetts, September 11, 2020 (Global News)-Biogen Inc. (NASDAQ: BIIB) today announced new data highlighting its extensive industry-leading multiple sclerosis (MS ) Efficacy and safety of the therapeutic combination. These data will be presented during the eighth joint meeting of MSVirtual2020, the American Multiple Sclerosis Treatment and Research Committee and the European Multiple Sclerosis Treatment and Research Committee (ACTRIMS-ECTRIMS), to be held from September 11 to 13, 2020.
“Biogen Chief Medical Officer Maha Radhakrishnan, MD, said: “Biogen is proud because we are committed to solving the urgent and long-term challenges faced by MS patients. “The data we provide on ACTRIMS-ECTRIMS highlights the improved results. Our extensive MS product portfolio continues to serve patients with relapsing MS, no matter where they are in the treatment process, and our continued research and development Invest in the development of potential effective drug candidates. ”
New Phase 3 data further characterize the effectiveness of VUMERITY® (Dilosimide fumarate) and patient-reported GI tolerance. New data from the VUMERITY Phase 3 clinical program further define Biogen’s latest oral fumarate therapy Effectiveness and safety. Compared with TECFIDERA® (dimethyl fumarate) (n = 251) and support, the results of the five-week EVOLVE-MS-2 study strengthened the gastrointestinal (GI) tolerance of patients assessed related to VUMERITY treatment The clinical significance of receptivity (n = 253) improves its impact on the quality of life of patients with recurrent MS. Participants in the study taking VUMERITY said that they are less likely to develop gastrointestinal symptoms that interfere with daily activities or are related to lack of work, and there are fewer drugs used to treat gastrointestinal symptoms.
An exploratory analysis of the ongoing EVOLVE-MS-1 study evaluated the effect of VUMERITY on brain volume changes and other clinical indicators in people with relapsed MS (n = 365) treated for up to two years. Separate studies have shown that decreased brain volume may be related to cognitive impairment, physical disability and decreased quality of life in MS patients. 1,2, the data of EVOLVE-MS-1 shows:
The annual brain volume change rate of study participants who received VUMERITY treatment for two years was similar to that of healthy individuals. with
Approximately 90% of patients receiving VUMERITY treatment have no confirmed disability progression, and approximately 84% have no recurrence within two years.
The final data from the Phase 3 study of ENDORSE will also be presented at the conference, which further proves the continuous efficacy and well-defined safety of TECFIDERA in patients up to 13 years.
Real data from a separate analysis of the recurrent MS population shows that through MS PATHS (Partner Advance Technology and Health Solutions), TYSABRI® (natalizumab), PLEGRIDY® (pegylated interferon beta-1a) And AVONEX® (interferon beta-1a) results have improved. , Biogen is collaborating with leading MS centers in Europe and the United States to generate standardized, high-quality data from various real-world MS patient populations. To date, more than 17,000 patients have participated in MS PATHS. The data obtained from the treatment in the real environment supports the improved results associated with TYSABRI, PLEGIDYY and AVONEX. The results of a separate analysis from the MS PATHS data indicate:
In the first comparison of the MS PATHS standard magnetic resonance imaging (MRI) regimen, the changes during the extended interval dosing period (EID; n = 85) of natalizumab were compared to the approved brain MRI (mean follow-up 0.8 years). Once every four weeks (Q4W; n = 569). The analysis reported no significant differences in the new T2 disease, T2 disease variables and brain atrophy rate. The differences in MRI scanners and acquisition protocols in clinical practice make the comparison of brain MRI results challenging. Multiple real-world studies have shown that the efficacy of natalizumab EID is similar to the approved Q4W dose. 3-7Biogen continues to evaluate the effectiveness, safety and tolerability of natalizumab EID through the prospective NOVA trial (NCT03689972), and has recently submitted an application for subcutaneous administration to the regulatory authority. If approved, It will provide more options for TYSABRI administration.
According to Neuro-QoL (Quality of Life in Nervous System Diseases) assessment, TYSABRI treatment has greater improvement in certain quality of life than Ocrevus® (ocrelizumab). In a subgroup analysis of matched patients treated with TYSABRI or Ocrevus, it was observed that 9 out of 12 Neuro-QoL domains in patients treated with TYSABRI were significantly improved (n = 144). 4 out of 12 domains improved significantly (n = 502)). Overall, the annual improvement rate of TYSABRI is higher than that of Ocrevus, and significant differences are observed in three aspects: positive influence and well-being, satisfaction with social roles and activities, and sleep disorders.
Compared with MS patients under 60 years old (n = 729), the clinical outcomes of MS patients over 60 years old (n = 286) showed that in both age groups, both PLEGRIDY and AVONEX can provide practical The therapeutic benefits. The data shows that the processing speed test (PST) and contrast sensitivity test (CST) of the two age groups have improved in more than one year. In addition, most participants in both age groups did not relapse within two years.
Data from the Phase 1 study of BIIB091 supports continued treatment of MSBiogen, and data from the Phase 1 study of BIIB091 is also provided. BIIB091 is a selective, reversible (non-covalent) small molecule inhibitor of the oral activity of Bruton’s tyrosine kinase (BTK) Agent. The data evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating oral doses in healthy adult subjects. Selective BTK inhibition can be beneficial to the treatment of MS by preventing the activation of B cells and myeloid cells without depletion of immune cells.
Data presentation on ACTRIMS-ECTRIMS: Note: All poster presentations of MSVirtual2020 will be available online at 8 AM Eastern Time on Friday, September 11, 2020.
Compared with the dimethyl fumarate in EVOLVE-MS-2, the improved GI tolerance of Diroximel fumarate is significantly related to the clinical significance of quality of life (Poster 0214)
The effect of Diroximel fumarate on brain volume changes and disability progression in adults with EVOLVE-MS-1 relapsing-remitting multiple sclerosis (Poster P0205)
Safety and effectiveness of patients treated with dimethyl fumarate and followed up for 13 years: the final results of ENDORSE (platform FC02.05-Sunday, September 13th 1:48-2:00 US Eastern Time)
The radiology results of patients with extended interval doses of Natalizumab are not different from the standard interval doses in MS PATHS (Poster P0360)
Effect of Natalizumab on the Quality of Life in a Real Cohort of Multiple Sclerosis Patients: Outcomes of the MS Pathway (Poster P1036)
Characteristics and clinical results of elderly MS patients with Peginterferon Beta-1a or intramuscular interferon Beta-1a in the treatment of MS pathway (Poster P0843)
Phase 1 study of BIIB091 (a Bruton’s tyrosine kinase (BTK) inhibitor) in healthy adult participants: preliminary results (poster P0186)
About VUMERITY® (Dilosemate Fumarate) VUMERITY is an oral fumarate with a chemical structure completely different from TECFIDERA® (Dimethyl Fumarate), approved in the United States for the treatment of multiple sclerosis in adults The recurring forms of the disease include clinically isolated syndromes, recurrent recurring diseases and active secondary progressive diseases. After entering the body, VUMERITY is quickly converted into monomethyl fumarate, the same active metabolite of dimethyl fumarate.
VUMERITY is contraindicated in patients who are allergic to Diroximel fumarate, dimethyl fumarate or any of the excipients of VUMERITY; and patients taking dimethyl fumarate. The serious side effects of VUMERITY are based on the data of dimethyl fumarate (the same active metabolite as VUMERITY), including allergic reactions and angioedema, progressive multifocal leukoencephalopathy, which is a rare opportunistic brain Viral infection is related to death or severe illness. Disability, decreased average lymphocyte count in the first year of treatment, shingles and other serious infections, liver damage and flushing. The most common adverse events obtained using data from dimethyl fumarate (with the same active metabolite as VUMERITY) were flushing, abdominal pain, diarrhea, and nausea.
Please click here for important safety information and complete prescription information, including patient information for VUMERITY in the United States.
About TECFIDERA® (dimethyl fumarate) TECFIDERA is a treatment method for relapsing multiple sclerosis (MS) in adults. It is the most prescribed drug for relapsing MS in the world. It has been proven to reduce the recurrence rate of MS and slow it down. It progresses to disability and affects the number of MS brain lesions, and proves that the characteristic safety of patients with relapsed MS is good. TECFIDERA has been approved in 69 countries/regions and has been treated for 475,000 patients, which means more than 950,000 patient-years of patients using and prescribing TECFIDERA. Of these, 6,335 patients (14,241 patient-years) came from clinical trials8.
TECFIDERA is contraindicated in patients who are allergic to dimethyl fumarate or any of the excipients of TECFIDERA. Severe side effects include allergic reactions and angioedema, and cases of progressive multifocal leukoencephalopathy (rare opportunistic brain viral infections associated with death or severe disability) have been observed in TECFIDERA patients with long-term lymphopenia, although The role of lymphopenia is uncertain in these cases. Other serious side effects include decreased average lymphocyte count during the first year of treatment, shingles and other serious infections, liver damage and flushing. In clinical trials, the most common adverse events associated with TECFIDERA were flushing, abdominal pain, diarrhea and nausea.
Please click here for important safety information and complete prescription information, including patient information for TECFIDERA in the United States, or visit the product website in your country/region.
About TYSABRI® (natalizumab) TYSABRI is an effective treatment for relapsing multiple sclerosis (RMS), which can be used for relapsing MS in adults. Clinical trials have proven that this treatment can slow the progression of physical disability and reduce The formation of new brain lesions and reduce recurrence. TYSABRI has been approved in 80 countries/regions. According to clinical trials and prescription data, TYSABRI has received TYSABRI treatment for more than 213,000 people worldwide, with more than 835,000 patient-years of experience. 9
TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), a rare opportunistic viral infection of the brain that has been associated with death or severe disability. The risk factor that increases the risk of PML is the presence of anti-JC virus antibodies, the use of immunosuppressive agents and TYSABRI for longer treatment. Patients with these three risk factors have the highest risk of PML. When starting and continuing treatment with TYSABRI, doctors should consider whether the expected benefits of TYSABRI are sufficient to offset this risk.
TYSABRI also increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella-zoster viruses. According to reports, MS patients receiving TYSABRI have severe, life-threatening and even fatal cases after the market. In the post-marketing environment, there are also clinically significant liver damage, including acute liver failure that requires transplantation. Other serious adverse events that occurred in patients treated with TYSABRI included hypersensitivity reactions (such as allergic reactions) and infections, including opportunistic infections and other atypical infections.
Please click here for important safety information, including boxed warnings, and complete prescription information, including the US TYSABRI medication guide, or visit the product website in your country/region.
About PLEGRIDY® (pegylated interferon β-1a) PLEGRIDY is a subcutaneous pegylated interferon, once every two weeks, for the recurrent form of multiple sclerosis (MS) in adults, which is the most common form of MS. Common form. PLEGRIDY is currently approved in more than 60 countries/regions, including the United States, Canada, Australia and Switzerland, and the entire European Union. According to prescription data, nearly 57,000 people worldwide have received PLEGRIDY treatment, with more than 107,000 patient-years of experience. 10Biogen continues to work to provide PLEGRIDY in other countries/regions around the world.
The effectiveness and safety of PLEGRIDY are supported by one of the largest pivotal studies, which used interferon therapy in patients with relapsing-remitting MS. In clinical studies, it has been proven that PLEGRIDY can significantly reduce the recurrence rate of MS, slow down the progression of disability and reduce the number of brain injuries in MS. At the same time, it has been proved that the safety of patients with relapsed MS is good. Reported side effects include liver problems, including liver failure and increased liver enzymes; depression or suicidal thoughts; severe allergic reactions; heart problems, including congestive heart failure; autoimmune diseases; decreased white blood cell or platelet counts; and seizures. In clinical trials, the most common adverse events associated with PLEGRIDY were injection site reactions and flu-like symptoms. A list of adverse events can be found in the complete PLEGRIDY product label for each recognized country.
Please click here for important safety information and complete prescribing information, including the U.S. PLEGRIDY drug treatment guidelines, or visit the product website in your country/region.
About AVONEX® (Interferon beta-1a) AVONEX is designated for relapsing MS, and it has been approved in more than 90 countries. According to prescription data, more than 580,000 people worldwide have received AVONEX treatment, with more than 2.6 million patient-years of experience. 11AVONEX is designated for the treatment of relapsing multiple sclerosis (MS), including clinically isolated syndromes, relapsing-adults with mild disease and active secondary progressive disease.
According to reports, patients receiving AVONEX have symptoms of depression, suicidal ideation or psychosis, and the frequency of suicide cases has increased. Few patients report severe liver damage, including liver failure. Rare cases of allergic reactions have been reported. Although beta interferon does not have any direct cardiac toxicity, it is reported that no patients with known susceptibility have developed congestive heart failure, cardiomyopathy, and cardiomyopathy of congestive heart failure. Post-marketing experience shows that peripheral blood cell counts are reduced. According to reports, patients using AVONEX have seizures, including those without a history of seizures. Autoimmune diseases of multiple target organs have been reported. It is recommended to perform regular blood chemistry, hematology, liver function and thyroid function tests on a regular basis.
Please click here for important safety information and complete prescribing information, including drug treatment guidelines for AVONEX in the United States, or visit the product website in your country/region.
About Biogen At Biogen, our mission is clear: we are pioneers in the field of neuroscience. Biogen discovers, develops and provides innovative therapies globally for people suffering from severe neurological diseases and neurodegenerative diseases and related treatments. Biogen is one of the world’s earliest global biotechnology companies, founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading drug portfolio for the treatment of multiple sclerosis, launched the first approved spinal muscle atrophy therapy, commercialized biosimilars of advanced biologics, and focused on advancing multiple sclerosis and neuroimmunology. Alzheimer’s disease and dementia, neuromuscular diseases, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neuropathy and pain.
We will regularly publish information that may be important to investors on our website www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor This press release contains forward-looking statements, including statements regarding the potential benefits, safety and effectiveness of VUMERITY, TECFIDERA, TYSABRI, PLEGIIDY and BIIB091 under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995; Results of some actual data; EVOLVE-MS-2 study, ENDORSE Phase 3 study and BIIB091 Phase 1 study results; MS identification and treatment; our MS treatment development plan; potential regulatory discussion, submission and approval and timing Arrangements; the potential of Biogen’s commercial business, including VUMERITY, TECFIDERA, TYSABRI, PLEGRIDY and BIIB091; and the risks and uncertainties associated with drug development and commercialization. These forward-looking statements can use words such as “target”, “expect”, “believe”, “can”, “estimate”, “expect”, “forecast”, “target”, “intend”, “may” To identify. “,” “plan”, “may”, “potential”, “will”, “will” and other words and terms with similar meanings. Drug development and commercialization involve a high degree of risk, and only a small number of research and development plans lead to product commercialization The results of early clinical trials may not represent complete results or the results of late or large-scale clinical trials, nor can they ensure regulatory approval. You should not rely excessively on these statements or the scientific data provided.
These statements involve risks and uncertainties, and may cause actual results to be materially different from the results reflected in such statements, including but not limited to the occurrence of adverse security incidents and/or unexpected concerns that may be caused by other data or analysis; unexpected expenses or delays Risks; Unexpected worries may arise due to other data, analysis or results during clinical trials; Unable to protect and enforce our data, intellectual property rights and other ownership, and uncertainties related to intellectual property claims and challenges ; Regulatory agencies may require additional information or further research, or may not be able to approve or may delay the approval of our drug candidates or the expansion of product labeling; failure to obtain regulatory approval in other jurisdictions; product liability claims; third-party cooperation risks; and The ongoing COVID-19 pandemic has direct and indirect effects on our business, operating results and financial conditions. Many but not all of the factors listed above may cause actual results to differ from our expectations in any forward-looking statements. Investors should consider this warning statement and the risk factors we have identified in our most recent annual or quarterly report and other reports we file with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and represent only the situation as of the date of this news release. Whether due to new information, future developments or other reasons, we do not undertake the obligation to publicly update any forward-looking statements.
Mowry EM, Beheshtian A, Waubant E, etc. The quality of life in multiple sclerosis is related to disease burden and brain volume measurement indicators. Neurology. 2009;72(20):1760-1765.
Lanz M, Hahn HK, Hildebrandt H. Brain atrophy and cognitive impairment in multiple sclerosis: a review [Published corrections are published in J Neurol. 2008 Feb; 255(2):309-10]. Journal of Neurology. 2007; 254 Supplement 2: II43-II48.
Foley J, Xiong K, Hoyt T, etc. The mild level of serum neurofilament in patients with relapsing-remitting multiple sclerosis was changed from natalizumab once every 4 weeks to extended interval administration. AAN 2020; S10.009.
Butzkueven, Kappos L, Spelman T, etc. Patients who switched to natalizumab for extended interval dosing or retained standard interval dosing had no significant difference in recurrence outcomes: comparative effectiveness analysis of the propensity score of patients in the TYSABRI observation program. ECTRIMS 2019; P1033.
Yamout B, Sahraian MA, Ayoubi NE, etc. Efficacy and safety of natalizumab administered at extended intervals. Mult Scler Relat Disord. 2018; 24: 113-116.
Zhovtis Ryerson L, Frohman TC, Foley J, etc. Extended interval administration of natalizumab in multiple sclerosis. J Neurol Neurosurgery Psychiatry. 2016;87:885-889.
Bomprezzi R, PawateS. Extended interval dosing of natalizumab: 7 years of experience in two centers. Ther Adv Neurol Disord. 2014; 7: 227-231.
As of June 30, 2020, based on combined after-sales data from clinical trials of prescription and exposure to TECFIDERA.
As of July 31, 2020, combined after-sales data based on prescription and clinical trials of TYSABRI exposure.
(Bloomberg)-SAP SE’s stock price fell as much as 21%, the biggest one-day drop since 1999. Previously, the Walldorf-based company lowered its full-year revenue forecast and said it expects a new round of revenue. Locked to the first half of 2021, demand has been undermined. In a test of Christian Klein, he became the exclusive CEO in April. The pandemic will delay SAP’s cloud revenue, overall sales and operating profit targets for a year or two, especially as the software company said in a statement on Sunday. SAP said that it expects limited growth and profit margins in the next two years, and will move its strategic plan for 2023 to 2025. Klein said in a conference call on Monday that he expects SAP to say in a statement that the previous outlook “assumes that the economy will reopen and population confinement will ease, leading to a gradual improvement in the demand environment in the third and fourth quarters.” The company recently predicted that by 2020, based on fixed exchange rates, adjusted revenues will reach 27.2 billion euros to 27.8 billion euros (32.2 billion to 32.9 billion US dollars), which is lower than expected and increased to 28.5 billion euros from the previous guidance of 27.8 billion euros. Euro. SAP also stated that its Concur business will no longer benefit from revenue related to travel this year. OddoBHF analyst Nicholas David wrote in a report that it is difficult to find some positive results from the results News. The market’s expectations for mid-term ambitions are/frightened, but new ambitions are lower than the most pessimistic expectations.” Qualtrics IPOSAP said its Qualtrics software division is in the advanced stage of listing. It announced in July that it decided to acquire the company at a record price and went public in the U.S. in less than two years. This was an unexpected turnaround and showed a strategic shift under Klein’s leadership. “We are very advanced in preparing for Qualtrics’ IPO,” Chief Financial Officer Luka Mucic said by phone on Monday. “Qualtrics’ strong quarterly performance will lay the foundation for further growth next year.” The new outlook adjusted cloud revenue is expected to increase from 8 billion euros to 8.2 billion euros in 2020, lower than the previous estimate of 8.3 billion euros to 8.7 billion euros. Euro Euro’s operating profit this year will be between 8.1 billion Euros and 8.5 billion Euros, which is lower than the expected 8.7 billion Euros. SAP has expanded its mid-term goal to exceed 36 billion Euros in total revenue by 2025 and will reach 35 billion Euros by 2023. , By 2025, cloud computing revenue will exceed 22 billion euros and operating profit will exceed 11.5 billion euros. Non-IFRS third-quarter operating profit in the third quarter fell 12% year-on-year to 2.07 billion euros. Compared with the 2.15 billion euros expected by analysts surveyed by Bloomberg, revenue during the period fell by 4% to 6.54 billion euros, while the average analyst forecast was 6.89 billion euros. , SAP CEO through PandemicU.K. The CMA draws its own way and begins an antitrust investigation against Sinch, the SAP division DealSAP is passed to JP Morgan Stanley, and JP Morgan conducts Qualtrics IPO (stock updates, other circumstances). Please visit Bloomberg.com to visit us and subscribe now. Maintain a leading position as the most trusted source of business news. ©2020 Bloomberg LP
A San Francisco accountant discussed the significance of the Biden administration to investment portfolios in every conversation with clients.
Users who have not placed an order on any platform of JD can receive discount coupons! With your Visa card, click to pay at JD.com for the first time and enjoy discounts!
Nobel laureate in economics, Yale University professor Robert Shiller urged investors to be cautious about the blockbuster stock market in a recent column in the New York Times.
The company said Lee Kun-hee, who built Samsung Electronics into a global giant in smartphones, semiconductors and TVs, died on Sunday after being hospitalized for more than six years with a heart attack on Sunday. Lee is 78 years old this year. He developed the Samsung Group into the largest conglomerate in South Korea and became the richest man in South Korea. Jeong Sun-, CEO of company research company Chaebul.com, said: “Lee’s amazing rise in Korea and how South Korea integrates into globalization is so symbolic that his death will be remembered by many Koreans.
Four years after the collapse of the BHS, has the audit industry that has been criticized for failing to find any problems changed?
According to CNBC reports, Jack Ma, the founder of Alibaba Group Holdings Limited (NYSE: BABA), said on Saturday that Ant Group’s dual initial public offerings (IPOs) in Shanghai and Hong Kong will become the world’s largest Listed company. What happened: CNBC said that the IPO price was Friday night, but Jack Ma did not disclose the specific number, which will be announced next week. Human history-has been determined outside of New York City. “Ma Yun said at the Shanghai Bund Summit. The Chinese billionaire called the issue a “miracle.” He said: “We didn’t dare to think about it five or even three years ago. “Ma Yun also called for banking reforms and for the establishment of a more inclusive new universal banking system. Why it matters: The initial public offerings of Alibaba-backed companies can generate nearly one billion in revenue, which will make it a Saudi Aramco The previous world’s largest initial public offering of US$29.4 billion. Aramco’s stock issued in December 2019 defeated Alibaba and won the crown of the largest IPO. According to reports, Singapore’s sovereign wealth fund GIC Private Limited may be listed in these two listings. The investment exceeds US$1 billion. According to Reuters, Singapore’s Temasek, an existing Ant investor, has also expressed interest in the stock. Price action: Alibaba’s stock price closed up nearly 1.2% on Friday to US$309.92. It rose by 0.11% during the after-hours trading session. More deals from Ben Singa *Click here to view Ben Singa’s option trades * Quibi collapses-this idea is not strong enough, Benzinga.com leadership (C) said in 2020: ” Or “Timing” is missing. Benzinga does not provide investment advice. all rights reserved.
Donate immediately to support the UN refugee agency, so that refugees can get emergency kits to deal with the rainy season and save them from disaster!
It is easy to buy stocks, but it is difficult to buy the right stocks without a time-tested strategy. So, what is the best stock to buy or put on the watch list now?
Futures fell sharply. The stock market may go with leaders like Microsoft and Tesla. With elections approaching and coronavirus cases surged, this was the highest income week.
Harry Markopolos (Harry Markopolos), a former derivatives professional who turned to an independent financial fraud investigator, discovered the $65 billion Bernie Madoff Ponzi scheme, but was ignored by the SEC For nine years. As an outspoken critic of US regulators, Harry now views the field of auditing and the insurance industry as the next major financial fraud case to be revealed.
Hang Seng’s new online tax-deductible annuity provides 10 years of additional fixed income and guarantees 1.73%-2% of internal income reset. It only takes about 10 minutes to apply for insurance online and act immediately.
Three people familiar with the matter said that the iPhone’s top assembler, Taiwan-based Foxconn, has set up a working group to resist the growing influence of Chinese electronics manufacturer Luxshare. The company believes that Luxshare constitutes its dominance. serious threat. One of the sources said that the project was initiated by Foxconn founder Guo Taiming and the target is Luxshare <002475.SZ> headquartered in Dongguan. The company is little known internationally, but is expected to become the first company to assemble in mainland China. Headquarters of iPhone-until now, turf is still dominated by Taiwanese manufacturers. The source said that the working group was established last year and has been investigating Luxshare’s technology, expansion plans, recruitment strategy and whether the company (currently only accounts for 5% of Foxconn’s revenue) is supported by any Chinese government entity.
This week’s main earnings and economic data report will be released later this week, and most FAANG stocks are reported after the close on Thursday.
AMD (AMD)’s third-quarter earnings report is scheduled to be released after the close on Tuesday, which is an interesting time for the semiconductor industry. The Wall Street Journal reported that AMD (AMD) plans to actively expand its business through potential acquisitions (XLNX) (XLNX). At the same time, its biggest competitor (INTC) has been working hard to continue to produce the advanced manufacturing technologies required to manufacture high-quality semiconductors.
Shop at major fashion online stores and spend with Visa card to enjoy up to 20% off! Discover the latest collections of Luisa Via Roma and Taylor now!
CFRA analyst Garrett Nelson said in an interview with Yahoo Finance on Friday that if Joe Biden (Joe Biden) wins the presidential election, Tesla (NASDAQ: TSLA) will be the biggest winner. What happened: Nielsen said that Tesla will be “one of the biggest companies” winners because the company is a “pure electric vehicle.” The analyst pointed out that the Biden government will provide substantial subsidies for electric vehicles. CFRA Analysts pointed out that Biden proposed “large scale expansion of electric vehicle tax credits” and “large construction of electric vehicle charging stations.” Nielsen said: “You are considering increasing the number of electric vehicle charging stations by about 20 times. It will really help the popularization of electric vehicles. “Important: During the last presidential debate in Tennessee last week, Biden said that his government will invest 50,000 electric car charging stations on the highway. The candidates say these charging stations will lead the United States to have a “future.” The former vice president believes that his vision for electric vehicles can address climate change and create “new high-paying jobs.” The company headed by Elon Musk announced the third quarter last week Revenue was US$8.77 billion, an increase of 39% year-on-year; Price action: Tesla shares closed down by nearly 1.2% on Friday to US$420.63. If Joe Biden wins the TSLA DateFirmActionFrom the latest in the October 2020 election Ratings Morgan Stanley maintains equal weights (October 2020) Canaccord Genuity maintains the trade-offs held in October 2020 and neutrally outperforms the broader market. See more analyst ratings for TSLA. See the latest analyst ratings* Benza’s latest analysis of the transaction* Rives Musk said that monthly rental services will be available next year. Jim Kramer said that Jim Tesla is a “crazy stock” in 2020 (C) Benzinga.com, which is “wrong” Benzinga does not provide investment advice. All rights reserved.
Which investment strategy has stood the test of time? Growth investment. Wall Street experts believe that stocks with excessive growth prospects reflect some of the most compelling stocks. This growth potential is beyond the immediate range, and these names will achieve substantial returns in 2020 and beyond. That said, to say the least, finding stocks that fall into this category can be challenging. Analysts believe that one strategy is to take a step back, look at the big picture, and focus on companies that have long-term growth based on impressive achievements year-to-date. Keeping this in mind, we used TipRanks’ database to identify three growth stocks that were highly rated by analysts. All three stocks have achieved considerable growth in 2020 and are ready to continue to climb. Pennsylvania National Game Company (PENN) First, we own the Pennsylvania National Game Company, which owns and operates gaming and racing facilities and video game terminal businesses in the United States. The name has soared 146% year-to-date, but some Wall Street analysts believe that there is still a lot of fuel in the tank. PENN recently announced its third quarter results in advance, which exceeded expectations. The company expects profit margins for the quarter to increase by more than 900 basis points, and adjusted EBITDAR will grow by 5% year-on-year, even if revenue is down 10% year-on-year. Five-star analyst Joseph Greff told clients that “JP Morgan Chase” stated: “The regional gaming industry recovery in May/June continued until the third quarter, and revenue was better than expected. Once suppressed demand After returning to normal, and since the previous COVID efficiency has improved, operating expenses have hardly / not climbed. We previously assumed that the growth rate was slowed down.” Having said that, Greif admitted that given the outstanding stock price performance, some other analysts have been Leave the relegation behind”. However, he still believes that “the value and catalyst for the future”. Analysts commented: “…There is a tug of war in investor sentiment. We believe this is healthy for stocks and is almost necessary for stocks to continue to rise; we believe that traditional gaming equity investors have not been completely bullied. We believe that investors are skeptical about PENN’s ability to compete with DraftKings, Fanduel, Caesars Entertainment, MGM/GVC, etc. PENN’s relative balance sheet size can fund the acquisition costs of early sports betting customers, but we believe , Given that the recent equity fundraising raised $950 million, the risk of this competition has been reduced within a meaningful range.” Most importantly, PENN recently launched the Barstool Sports betting app in Pennsylvania. Greff called this early release “encouraging in terms of both volume and marketing expenditure,” and it proved “the potential for a unique approach to gaining share.” In addition, the momentum of Barstool Sportsbook is increasing. More importantly, Greff believes that the current sports betting and iGaming environment is similar to the rise of regional markets in the 1990s, when states with budget deficits turned to new sources of income, such as riverboat games to help cover their budgets. deficit. In this regard, the analyst said: “We believe that each state has almost the same expectations for USSB and iGaming, and PENN will be one of the winners. We like the land-based gaming/sports betting/iGaming pattern in the US and see room for growth. .” Well, it’s no surprise that Grave stayed with the Bulls. In addition to giving an “overweight” rating, he also set a price target of $83 for the stock. If this goal is achieved within the next twelve months, investors may get a 32% return. (To watch Greif’s track record, click here.) What does the rest of Wall Street have to say? Nine buys, three holds and one sell were issued in the last three months. As a result, PENN received a “medium buy” consensus rating. Based on the average price target of $76.77, the stock price may rise by 22% next year. (See Penn National Gaming stock analysis on TipRanks.) Redfin (RDFN) Redfin started with a map-based search space and expanded its product range to make family games, debuts and hosting processes faster and easier. On Wall Street, some people think that the name is not just about the surge in COVID demand, and its 113% year-to-date gain is just the beginning. Although RDFN got rid of the strong third-quarter forecast, investors were somewhat disappointed by the result. BTIG’s Jake Fuller pointed out that the stock price may fall because “expectations are high and a moderate increase in income scale is about 2%” and “momentum investors tend to reward a volume-led rhythm, while RDFN actually lags behind this expectation.” Fuller believes that RDFN is not the focus of many people’s attention, which indicates that investors may not have seen the earnings disclosure. However, he thinks Wall Street may miss the key part of the puzzle. The five-star analyst mentioned: “What may be overlooked here is that RDFN has increased the commission rate without significant impact on the conversion rate, which will greatly enhance the outlook for RDFN’s gross profit.” To this end, he will The 2021 gross profit is expected to increase by 47%. Looking closely at the detailed information for the quarter, RDFN experienced strong demand and real estate services revenue grew 36% year-on-year. Website traffic and transaction volume also increased month-on-month. However, it should be noted that the upside is driven by the revenue of each transaction. Fuller said: “This is important because it shows that the expected commission rate will eventually contribute.” “According to our statistics, real estate services revenue from 1.68% of GTV in the third quarter of 2019 and the second quarter of 2020 1.78% increased to an estimated 1.85% in the third quarter of 2020. A four-point high gross margin indicates high traffic in this area. Although it is difficult to assess the persistence of demand, price increases and better profit margins should be sustainable “Fowler commented. Consistent with his optimism, Fuller supported the bulls, reiterating a buy rating and a target stock price of $65. This goal expresses his confidence in RDFN’s ability to increase by 45% next year. (To view Fuller’s track record, click here.) When moving to other parts of Wall Street, opinions were even more divided. In the past three months, 6 buys, 5 holds and 1 sell were allocated. According to Wall Street, RDFN is a medium buy. The average price target of $50 means 11% upside. (See Redfin stock analysis on TipRanks) Vertiv Holdings (VRT) As one of the world’s leading hardware, software and service providers, Vertiv Holdings has helped to promote the interconnected market of digital systems, in which a large number of indispensable The data needs to be transmitted, analyzed, processed and stored. Wall Street said it has risen 71% so far this year, and there may be more gains. Even if the stock price rises sharply, Wolfe Research analyst Nigel Coe still believes that the risk/reward situation is good. He explained: “We believe that Vertiv is a rare species that can attract a wide range of investors: a medium-sized growth company that can provide attractive profit growth at a discount and is under the responsibility of a top executive team.” When it comes to VRT On the road to growth, its main end markets are data centers and telecommunications. These spaces are the areas where Coe expects to achieve growth in 2020 and 2021, as well as the long-term long-term disadvantages brought about by the continuous increase in data intensity and 5G upgrades. In addition, driven by efforts to keep fixed costs constant through various operational upgrades and reducing organizational complexity, management outlined a way to expand profits to 500 basis points. “This is a script successfully deployed by executive chairman David Cote during his tenure at Honeywell, which convinces us that similar scripts can be deployed in Vertiv,” Cohen said. It is worth noting that VRT withdrew in the second quarter of 2020, with net debt of approximately US$2.1 billion and net debt/EBITDA reaching 4.2 times. Even at the high end of this range, Coe believes that the balance sheet may deleverage quickly. To this end, he assumes that by 2023 the net debt/EBITDA ratio is twice, then the remaining capital will reach 1 billion US dollars. “We do not currently think that Vertiv is a clear capital deployment story, but this may surface within the time frame of 2022/23-we can of course see acquisition activities to enhance its capabilities in the power distribution field and the DCIM layer. Other possible options include the liquidation of cash warrants (these are currently reflected in our diluted share count calculation) and the way in which dividends are distributed, which will expand the possibility of institutional ownership. We also cannot ignore the fact that many larger electrical equipment The scope of strategic partnerships established by market participants, these participants are not important participants in the data center.” Everything VRT has done persuaded Coe to reiterate its outperform rating. While calling options, he set a price target of $23, implying a 22% upside potential. (To view Coe’s track record, click here) Do other analysts agree? they are. In the last three months, only 4 exact “buy” ratings have been published. Therefore, the message is clear: VRT is a strong buy. Given that the average target price is $20.75, the stock price may rise by 10% next year. (See Vertiv Holdings stock analysis on TipRanks) Disclaimer: The views expressed in this article are only those of the main analyst. The content is for reference only. Before making any investment, it is very important to conduct your own analysis.
Microsoft, Apple, Alphabet, Facebook, Amazon, AMD, Caterpillar, Comcast, GE, Ford, Pfixer, Visa, UPS, Exxon Mobil, Twitter and other companies reported their third quarter results.
A new sharing platform for Hong Kong SMEs-”HSBC Airport” connects you to different business information and events
In the week ending October 22, mortgage interest rates fell to record lows. It is expected that COVID-19 and American politics will continue to have an impact this week.
Trifecta Stocks will identify bearish stocks every Wednesday, and there may be some interesting investment opportunities in the short term. Using technical analysis of these stock charts, and where appropriate, based on TheStreet’s Quant Ratings’ latest actions and ratings, we zeroed out the five names. Although we will not consider fundamental analysis, we hope that this article will provide investors interested in stocks with a good starting point for further homework on the name.
After years of working on American shale gas, Chevron is betting its natural gas future in the volatile region of the Middle East, and energy professionals have long been cautious. The company’s chief executive Michael Wirth’s decisive move is supported by the bet that the Middle East is entering an era of reconciliation, which will make it an ideal choice for natural gas extraction, as it is expected to be less expensive than cheap and clean fuels. Demand will exceed oil. The new strategy is that the company promotes new natural gas transactions in Egypt, Israel, and Qatar, while reducing spending on shale exploration in the United States.